[SGYP] Synergy Pharmaceuticals, Inc.
Overview
Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization:
Exchange: NASDAQ
The data is delayed by 15 minutes.
Strongest Trends Summary For SGYP
SGYP is in the medium-term up 253% in 3 weeks and down -87% in 4 months and down -88% below S&P in 1 year. In the long-term down -96% below S&P in 3 years.
Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max
Chart type: absolute | relative to S&P
Description: Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate is plecanatide, a guanylyl cyclase C receptor agonist that is in Phase III clinical trials to treat chronic idiopathic constipation GI disorders, as well as is in Phase IIb clinical trials for the treatment of constipation-predominant irritable bowel syndrome GI disorders. The company also develops SP-333, which is in Phase II clinical trials to treat GI inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals Inc. is headquartered in New York, New York.
Fundamental Ratios
| Shares Outstanding | EPS | EPS Growth - 4 Quarters | EPS Growth - Q/Q | ||||
| EPS Growth - Y/Y | Sales Growth - 4 Quarters | Sales Growth - Q/Q | P/E | ||||
| P/E To EPS Growth | P/S | P/BV | Price/Cash Per Share | ||||
| Price/Free Cash Flow | ROA | -54.85% | ROE | 432.02% | ROI | ||
| Current Ratio | 9.53 | Quick Ratio | Long Term Debt/Equity | 1.23 | Debt Ratio | -0.77 | |
| Gross Margin | Operating Margin | Net Profit Margin | Dividend Payout Ratio | ||||
| Dividend Yield |
Fundamental Data
| Cash From Financing Activities | 5.41 M | Cash From Investing Activities | -50.01 M | Cash From Operating Activities | -23.15 M | Gross Profit | |
| Net Profit | -27.39 M | Operating Profit | -22.8 M | Total Assets | 194.83 M | Total Current Assets | 182.28 M |
| Total Current Liabilities | 19.13 M | Total Debt | 200 M | Total Liabilities | 219.57 M | Total Revenue |
Technical Data
| High 52 week | 2.64 | Low 52 week | 0.08 | Last close | 0.09 | Last change | -18.15% |
| RSI | 16.15 | Average true range | 0.05 | Beta | 0.78 | Volume | 31.45 M |
| Simple moving average 20 days | -71.25% | Simple moving average 50 days | -86.2% | Simple moving average 200 days | -94.19% |
Performance Data
| Performance Week | -45.88% | Performance Month | -77.91% | Performance Quart | -94.94% | Performance Half | -95.8% |
| Performance Year | -95.67% | Performance Year-to-date | -96.12% | Volatility daily | 21.8% | Volatility weekly | 48.74% |
| Volatility monthly | 99.88% | Volatility yearly | 346.01% | Relative Volume | 577.63% | Average Volume | 8.71 M |
| New High | New Low |
News
2019-01-09 08:03:43 | See what the IHS Markit Score report has to say about Synergy Pharmaceuticals Inc.
2019-01-07 10:46:20 | [$$] Charlotte Russe Reassesses Its Future, Including Sale or Bankruptcy
2019-01-04 17:52:13 | [$$] Synergy Pharmaceuticals Wins Court Approval for Extended Sale Process
2019-01-04 10:10:00 | These 4 Healthcare Stocks Are Making Moves
2019-01-02 11:55:00 | These 4 Healthcare Stocks Are Kicking Off The New Year With A Bang
2018-12-31 08:59:00 | 4 Pharma Stocks Gaining Speed on Monday 12/31/18
2018-12-28 13:33:17 | [$$] Firm Retention Summary: Synergy Pharmaceuticals Inc.
2018-12-21 10:45:00 | These 4 Pharma Stocks Could Test December Highs
2018-12-20 08:02:09 | See what the IHS Markit Score report has to say about Synergy Pharmaceuticals Inc.
2018-12-19 12:30:00 | These 4 Pharma Stocks Are Heating Up
2018-12-18 06:50:00 | Today's Research Reports on Trending Tickers: Achillion Pharmaceuticals and Synergy Pharmaceuticals
2018-12-18 06:40:00 | 4 Stocks to Watch Pre-Market on Tuesday 12/18/2018
2018-12-17 13:30:00 | 4 Stocks Providing Investor Opportunity Right Now
2018-12-17 10:33:22 | [$$] Neiman Marcus Asks Court to Dismiss Lawsuit by Marble Ridge
2018-12-17 07:00:00 | Cipher Pharmaceuticals Announces PLECANATIDE Accepted for Review by Health Canada
2018-12-14 13:50:14 | [$$] Synergy Pharmaceuticals Kicks Off Path Toward Sale
2018-12-13 09:02:02 | Bausch BHC Bids for Assets of Synergy Pharmaceuticals
2018-12-13 06:55:00 | Today's Research Reports on Trending Tickers: Neurocrine Biosciences and Synergy Pharmaceuticals
2018-12-12 13:21:16 | No Emoji Could Hide This Drugmaker’s Woes
2018-12-12 12:36:14 | Synergy Pharmaceuticals Bankruptcy: SGYP Stock Plummets on Filing
2018-12-12 10:40:33 | [$$] Former Pharma Highflier Appreciates Bathroom Humor
2018-12-12 09:36:07 | [$$] Bausch Health Agrees to Buy Synergy Pharmaceuticals for $200 Million
2018-12-12 07:43:00 | UPDATE: Synergy Pharma shares slide 55% as it files for Chapter 11, clearing way for sale too Bausch
2018-12-12 07:30:00 | Synergy Pharma shares slide 29% as it files for Chapter 11, clearing way for sale too Bausch
2018-12-12 06:30:00 | Bausch Health Enters Into Definitive _Stalking Horse_ Agreement To Acquire Substantially All The Assets Of Synergy Pharmaceuticals Inc.
2018-12-12 06:00:00 | Synergy Pharmaceuticals Announces Agreement for Bausch Health to Acquire Its Business Assets
2018-12-06 08:02:23 | See what the IHS Markit Score report has to say about Synergy Pharmaceuticals Inc.
2018-11-24 08:03:52 | See what the IHS Markit Score report has to say about Synergy Pharmaceuticals Inc.
2018-11-13 08:25:00 | Recent Analysis Shows Brown Forman, CryoLife, Aspen Group, Taylor Devices, Synergy Pharmaceuticals, and Ramco-Gershenson Properties Trust Market Influences — Renewed Outlook, Key Drivers of Growth
2018-11-13 08:02:39 | See what the IHS Markit Score report has to say about Synergy Pharmaceuticals Inc.
2018-11-08 20:30:01 | Synergy Pharmaceuticals SGYP Reports Q3 Loss, Misses Revenue Estimates
2018-11-08 19:26:07 | Synergy Pharma: 3Q Earnings Snapshot
2018-11-08 17:00:00 | Synergy Pharmaceuticals Reports Third Quarter 2018 Financial Results and Business Update
2018-11-02 10:49:24 | What We Can Learn From Synergy Pharmaceuticals' Disastrous News
2018-11-01 20:21:00 | Scary Markets, Frightening Stocks, and How to Keep From Panicking
2018-10-31 17:00:00 | Synergy Pharmaceuticals Names Dr. Melvin K. Spigelman Chairman
2018-10-26 16:55:45 | Why Synergy Pharmaceuticals, Tesla, Tencent and More Are Trending
2018-10-26 10:45:26 | [$$] Investors Frown on Biotech Famed for Emojis
2018-10-26 10:45:00 | Why Synergy Pharmaceuticals Is Being Obliterated Today
2018-10-25 17:00:00 | Synergy Pharmaceuticals Provides Business Update
2018-10-08 08:00:00 | Synergy Pharmaceuticals Presents New Analyses Supporting the Use of TRULANCE® plecanatide in Two Patient Populations at the American College of Gastroenterology ACG Annual Scientific Meeting
2018-10-03 09:41:01 | Is the Options Market Predicting a Spike in Synergy Pharmaceuticals SGYP Stock?
2018-10-01 09:30:00 | Synergy Pharmaceuticals to Present New Analyses of TRULANCE® Plecanatide at the American College of Gastroenterology ACG Annual Scientific Meeting
2018-09-24 08:00:00 | Synergy Pharmaceuticals Strengthens Coverage for TRULANCE® plecanatide with Key New Market Access Wins
2018-09-19 15:03:00 | Shareholders Should Check If Insiders Own Shares In Synergy Pharmaceuticals Inc NASDAQ:SGYP
2018-09-15 08:04:01 | See what the IHS Markit Score report has to say about Synergy Pharmaceuticals Inc.
2018-09-11 09:12:00 | Here's Why Synergy Pharmaceuticals Rose 14.1% in August
2018-08-31 08:46:12 | Are Options Traders Betting on a Big Move in Synergy Pharmaceuticals SGYP Stock?
2018-08-23 08:07:06 | See what the IHS Markit Score report has to say about Synergy Pharmaceuticals Inc.